What you're describing is a single clinical trial outcome, and that alone isn't enough to set a standard of care. Medical associations typically hold off until several trials line up—or until whatever evidence threshold they use is met—before they put out guidelines. The standard of care comes from those guidelines, not from one study.randompersonrandom said:
Sasquatch said:
Does this group—those of us here on this forum—even register as real to doctors who are licensed and practicing? We hold a mountain of information since we guide ourselves. Yet I doubt a single physician could show up here, within the rules of their license, just to pick up what we, this community, have learned.randompersonrandom said:
It’s odd that they frame it as "stopping," as though that wouldn’t just lead to regaining the weight, which we basically KNOW will happen. Reducing the dose, fine, but quitting entirely? What for—so you can repeat the whole thing 12 months from now?![]()
tubby said:
The reason is simply that using GLPs to treat obesity is a relatively recent approved mode of treatment. Drug companies understand that acceptance of GLPs goes up when people believe the pitch is "use it for several months, shed the pounds, then you're finished" — which is why maintenance isn't being emphasized heavily at this stage. Right now the priority is gaining entry by securing reimbursement from health plans, and presenting the drug as short-term makes that argument far easier to win.randompersonrandom said:
It’s odd that they frame it as "stopping," as though that wouldn’t just lead to regaining the weight, which we basically KNOW will happen. Reducing the dose, fine, but quitting entirely? What for—so you can repeat the whole thing 12 months from now?
After pharma judges that GLPs have hit critical mass for weight-loss use and insurance coverage, it will then encourage endocrinologists — through whichever professional societies are relevant — to begin putting out formal positions on maintenance treatment. By that point, health plans will find it much harder to walk back coverage, leaving them on the hook for lifetime payment (along with the steeper premiums that follow).
Sure, but...SURMOUNT actually took place. Everyone watched it unfold. They keep acting like it never occurred, yet it did, and to me that's just astonishing.
My hunch is that they'll arrive at that point right around the time most health plans start offering some form of temporary GLP coverage for obesity. Take SURMOUNT—you'd imagine that would have been enough, yet it'll probably be whichever trial wraps up at that moment that finally tips the scales to "just enough" for them to feel ready to publish guidelines.